Search the Newsreel

Alkermes PLC (ALKS) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst Competitive ...

This article first appeared on GuruFocus. Release Date: July 28, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Alkermes PLC (NASDAQ:ALKS) reported a 34% year-over-year increase in net sales from its proprietary product …

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

Alkermes plc reported break-even earnings for Q2 2026, surpassing the Zacks Consensus Estimate of a loss, while revenues of $496 million beat estimates. The company saw a 27% increase in total revenues year-over-year, driven by strong proprietary product sales, yet its stock declined in …

Alkermes plc Revenue Breakdown – NASDAQ:ALKS

(ALKS) Risk Channels and Responsive Allocation

This article provides an AI-driven analysis of Alkermes Plc (NASDAQ: ALKS), focusing on risk channels and responsive allocation strategies. It highlights strong near-term sentiment with a potential shift to long-term positive bias, noting a significant risk-reward short setup. The analysis outlines three specific trading …

Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Alkermes (ALKS) reported revenue of $496.01 million, up 27% over the same period last year. EPS came in at $0, compared to $0.52 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $453.98 …

Alkermes beats Q2 estimates, reaffirms revenue guidance

Alkermes plc reported strong second-quarter financial results, surpassing analyst expectations with adjusted earnings per share of $0.00 and revenue of $496.0 million, a 27% increase year-over-year. The company reaffirmed its full-year 2026 revenue guidance, citing strong performance across its proprietary product portfolio, particularly LUMRYZ, …

Alkermes plc Reports Second Quarter 2026 Financial Results

DUBLIN, July 28, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a …

Alkermes (ALKS) Reports Break-Even Earnings for Q2

Alkermes (ALKS) Could Be 11% Above Fair Value As Earnings Land】【。

TALK|Talkspace Inc|Price:5.225|Chg%:+0.015

Talkspace Inc. (TALK) is a virtual behavioral healthcare company with strong fundamentals and high growth potential, though its valuation is considered fairly valued. Institutional ownership is high, and analysts currently rate the stock as "Hold" with a target price of $6.125. The stock's price …

Talkspace Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed company profile of Talkspace Inc. (TALK), a virtual behavioral healthcare provider. It covers the company's business scope, key financial data such as market cap and P/E ratio, and lists important company executives and their shareholdings. The report also highlights …

Talkspace Inc (TALK) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Talkspace Inc (TALK), outlining its major shareholders and institutional holdings. It presents data on key investors like Hudson Executive Capital LP and BlackRock, along with a breakdown of shareholder types and a historical view of institutional shareholding …

Talkspace Inc (TALK) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Talkspace Inc (TALK), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, TALK is currently suitable for range-bound swing trading, with a neutral signal based on …

Talkspace Inc (TALK) Cash Flow

This article provides a detailed quarterly cash flow statement for Talkspace Inc (TALK), encompassing operating, investing, and financing activities from FY2020Q1 to FY2026Q1. It breaks down various cash flow components and includes FAQs explaining operating, investing, and financing cash flows, as well as free …

TALK|Talkspace Inc|Price:5.250|

TALK|Talkspace Inc|Price:5.245|Chg%:+0.005

Talkspace Inc. (TALK) is a virtual behavioral healthcare company with strong fundamentals and high growth potential, though its valuation is considered fairly valued. Institutional ownership is high, and analysts currently rate the stock as "Hold" with a target price of $6.125. The stock's price …

Alkermes plc (8AK) Q3 2025 Earnings Report - Results, Call & Slides

Alkermes plc (8AK) reported its Q3 2025 earnings, achieving an actual EPS of €0.60, significantly beating the consensus of €0.32. The company also surpassed revenue expectations with €346.21M against an anticipated €313.46M, marking a YoY revenue growth of 4.24%. The next earnings release is …

Talkspace Inc (TALK) Institutional Confidence

Talkspace Inc (TALK) has an institutional shareholding score of 7.00, placing it 37th out of 75 in the Healthcare Providers & Services industry. The institutional shareholding proportion is 75.25%, an increase of 22.04% quarter-over-quarter. George Soros is the largest institutional shareholder with 2.75 million …

Talkspace Inc (TALK) Financial Health: Profitability & Balance Sheet Analysis

Talkspace Inc (TALK) has a robust financial score of 8.02, placing it 30th out of 75 in the Healthcare Providers & Services industry due to strong operating efficiency. The company recently reported a 18.20% year-over-year revenue increase and a remarkable 2083.02% rise in net …

ALKS Crosses Above Average Analyst Target

In recent trading, shares of Alkermes plc (Symbol: ALKS) have crossed above the average analyst 12-month target price of $52.83, changing hands for $52.97/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

ETFs Investing in Talkspace, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Talkspace, Inc. (TALK). It provides a detailed table including each fund's market value, weight of TALK stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, …

Price to book forward of Talkspace, Inc. – NASDAQ:TALK

This page provides financial data for Talkspace, Inc. (NASDAQ: TALK), specifically focusing on its price to book forward metric. The content indicates that the market is closed and no trades have been made, offering an overview of the company's financials for investors.

Alkermes (ALKS) to Post Earnings on Tuesday

Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Enterprise value to EBITDA forward of Talkspace, Inc. – NASDAQ:TALK

This article presents the enterprise value to EBITDA forward for Talkspace, Inc. (NASDAQ: TALK), indicating a financial metric for the company. It lists the period, value, and change associated with this metric. The content is primarily a data point rather than a textual analysis.

Stifel raises Alkermes stock price target on orexin program outlook By Investing.com

Stifel has increased its price target for Alkermes (NASDAQ:ALKS) to $63, up from $45, while maintaining a Buy rating. The adjustment reflects positive expectations for the company's idiopathic hypersomnia program and potential in its ADHD program, both leveraging orexin treatments. Despite the stock trading …

Alkermes Plc (ALKS) Stock Analysis: Growth Potential With A 28.20% Revenue Surge

Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?

Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear

Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Earnings call transcript: Alkermes Q1 2026 results beat expectations, stock rises

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside

Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?

ALKERMES ($ALKS) Releases Q4 2025 Earnings